ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1240

A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study

Kenneth Saag1, Alexander So 2, Puja Khanna 3, Robert Keenan 4, Sven Ohlman 5, Torbjörn Kullenberg 5, Lisa Osterling Koskinen 5, Michael Pillinger 6 and Robert Terkeltaub 7, 1University of Alabama at Birmingham, Birmingham, AL, 2Université de Lausanne, Lausanne, Switzerland, 3University of Michigan Medical School, Ann Arbor, 4Duke University School of Medicine, Durham, 5Sobi, Stockholm, Sweden, 6New York University School of Medicine, New York, 7San Diego VA/UCSD, San Diego, CA

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Anakinra, clinical trials, gout, randomized trials and IL-1

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Monday, November 11, 2019

Session Title: Metabolic & Crystal Arthropathies Poster II: Clinical Trials & Basic Science

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: In gout, urate crystals deposited in and around joints trigger episodes of acute arthritis, mediated by the proinflammatory cytokine IL-1β. In uncontrolled studies, the IL-1 receptor antagonist anakinra appears effective in reducing pain and signs of acute flares in patients with difficult-to-treat gout. However, confirmatory, adequately-powered, prospective trials are lacking. The ‘anaGO-study’ (anakinra in gout) was a multi-center, randomized, double-blind, double-dummy, phase 2 study investigating the efficacy and safety of anakinra in acute gout (NCT03002974).

Methods: Patients were recruited who had acute gout based on ACR/EULAR 2015 gout classification criteria, and were unsuitable for anti-inflammatory therapy with NSAIDs and colchicine due to contraindication, intolerance or inefficacy. The primary objective was to evaluate the efficacy of two regimens of anakinra (100 or 200 mg daily s.c. injections for 5 days) compared to triamcinolone (single i.m. injection 40 mg) with respect to patient-assessed pain intensity. Patients were randomized to each group in a 1:1:1 ratio and stratified by urate-lowering therapy use (yes/no) and BMI (< 30.0 or ≥30.0 kg/m2). The primary endpoint was change in pain intensity from baseline to 24-72 hours (average of 24, 48 and 72 hours) in the most affected joint measured on a visual analogue scale (0-100 VAS). Secondary outcomes included: time to onset of effect, time to response, time to pain resolution, time to rescue medication use, patient’s and physician’s assessments of global response, clinical signs, inflammatory biomarkers, and safety.

Results: 165 patients were randomized; 110 to anakinra (56 to 100 mg/day, 54 to 200 mg/day) and 55 to triamcinolone; 108 and 53 were included in the primary analysis, respectively. The median (range) age was 55 (25-83) years, 87% were male, mean disease duration was 8.7 years and mean number of self-reported flares during the past year was 4.5. The pain intensity, from baseline to 24-72 hours, decreased in both treatment groups; mean (95% CI) change was -39.4 (-46.8, -32.0) for triamcinolone and -41.2 (-46.3, -36.2) for anakinra. The 100 mg and 200 mg doses of anakinra were comparably effective in decreasing pain (100 mg/day: -41.8 [-48.9, -34.8] and 200 mg/day: -40.7 [-47.9, -33.4]). Mean (95% CI) difference in pain reduction between anakinra and triamcinolone treatment groups was -1.8 (-10.8, 7.1) (p-value = 0.688 for primary endpoint). The majority of secondary efficacy endpoints were numerically in favor of anakinra, and in most instances also statistically significant, in comparison to triamcinolone, e.g. physician’s assessment of clinical signs at 72 hours and patient’s and physician’s assessment of global response at Day 8. No unexpected safety findings were identified in any of the treatment groups.

Conclusion: Anakinra and triamcinolone reduced patient-assessed gout flare pain to similar degrees in patients for whom conventional therapy was ineffective or contraindicated. Both doses of anakinra showed comparable efficacy in pain reduction. The majority of secondary efficacy endpoints favored anakinra. Anakinra was shown to be an additional option for use during acute gout flares.


Disclosure: K. Saag, Abbvie, 5, AbbVie, 5, Amgen, 2, 5, Ampel, 2, Bayer, 5, Gilead, 5, Horizon, 2, 5, Ironwood/AstraZeneca, 2, 5, Kowa, 5, kowa, 5, Mereo, 2, Radius, 5, Radius Health, 2, 5, Roche/Genentech, 5, SOBI, 2, 5, Sobi, 2, 5, Takeda, 2, 5, Teijin, 5, Tejin, 5; A. So, Sobi, 5, Grunenthal, 5; P. Khanna, Horizon, 5, Sobi, 5; R. Keenan, Sobi, 5, Selecta, 5, Horizon, 5; S. Ohlman, Sobi, 1, 3; T. Kullenberg, Sobi, 1, 3; L. Osterling Koskinen, Sobi, 1, 3; M. Pillinger, Sobi, 5, Horizon, 5; R. Terkeltaub, Astra-Zeneca, 2, 5, Horizon, 5, Selecta, 5, SOBI, 5, Sobi, 5.

To cite this abstract in AMA style:

Saag K, So A, Khanna P, Keenan R, Ohlman S, Kullenberg T, Osterling Koskinen L, Pillinger M, Terkeltaub R. A Randomized, Phase 2 Study Evaluating the Efficacy and Safety of Anakinra in Difficult-To-Treat Acute Gouty Arthritis: The anaGO Study [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-randomized-phase-2-study-evaluating-the-efficacy-and-safety-of-anakinra-in-difficult-to-treat-acute-gouty-arthritis-the-anago-study/. Accessed March 1, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-randomized-phase-2-study-evaluating-the-efficacy-and-safety-of-anakinra-in-difficult-to-treat-acute-gouty-arthritis-the-anago-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.